MCL Literature Feed
50 papers on mantle cell lymphoma from PubMed. Updated daily.
A rare case of co-existing CNS DLBCL and systemic MCL was successfully treated with a multi-modal approach including chemotherapy, ibrutinib bridging, and autologous transplant, achieving 3-year remission.
This review summarizes how BTKi integration into frontline therapy (TRIANGLE trial) challenges the role of transplant, while CAR-T cells are established as the best option after BTKi failure.
This comprehensive review outlines evolving frontline MCL strategies, highlighting the integration of targeted agents, re-evaluation of transplant, and the emerging role of MRD-guided therapy to improve outcomes.
For younger MCL patients post-transplant, this phase III analysis shows conditional survival improves over time, especially after R-CHOP, providing data for dynamic prognostication and reinforcing intensive induction.
An MCL patient post-autologous transplant developed persistent COVID-19 with a novel Remdesivir resistance mutation, highlighting the risk of immunocompromised hosts becoming reservoirs for drug-resistant SARS-CoV-2 variants.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This study evaluates the outcomes of Rituximab-Bendamustine (RB) versus the CHASER regimen as induction therapy for transplant-eligible mantle cell lymphoma, informing pre-transplant treatment selection.
This 20-year Taiwanese retrospective study confirms that frontline rituximab, intensive chemotherapy, and autologous transplant are associated with improved survival, validating these established strategies in a real-world Asian cohort.
Reviewing the TRIANGLE trial, this paper argues that adding ibrutinib to frontline induction makes omitting autologous stem cell transplant consolidation a non-inferior, less toxic option for young patients.
Long-term follow-up after autologous stem cell transplant in MCL is critical for detecting late relapses and managing treatment-related toxicities, guiding post-transplant surveillance strategies.
This review highlights that excellent outcomes with modern frontline chemo-immunotherapy plus BTK inhibitors are challenging the traditional role of autologous transplant consolidation in mantle cell lymphoma.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This case of atypical plasma cell leukemia, initially misdiagnosed as blastoid mantle cell lymphoma, highlights the critical diagnostic challenge of distinguishing between aggressive, morphologically similar hematologic malignancies.
Analysis of the FIL MCL0208 trial shows that stem cell collection and subsequent hematological recovery are feasible and safe in young, fit MCL patients undergoing frontline autologous transplant consolidation.
For transplant-eligible MCL, substituting rituximab with obinutuzumab in chemo-immunotherapy induction and maintenance significantly improved MRD negativity, 5-year progression-free survival (83% vs 67%), and overall survival.
A case of primary ocular adnexal MCL demonstrates its potential for rapid systemic progression, emphasizing the need for thorough initial staging and aggressive systemic therapy despite localized presentation.
In young, newly diagnosed MCL patients, adding ibrutinib to chemoimmunotherapy improves failure-free survival, establishing a new standard and questioning the necessity of autologous stem cell transplant consolidation.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
The phase 3 TRIANGLE trial established that adding ibrutinib to induction/maintenance allows omission of autologous transplant in young, fit MCL patients, providing a new frontline, transplant-free standard.
Outpatient autologous stem cell transplantation is a feasible consolidation strategy for advanced MCL in a low-income, Latin American setting, providing important real-world evidence for resource-constrained systems.
This review positions allogeneic transplant as a key curative option for high-risk (e.g., TP53-mutated) and relapsed/refractory MCL, despite its changing role with the advent of novel therapies.
This case of asymptomatic multiple lymphomatous polyposis in an elderly MCL patient demonstrates that significant GI involvement can be clinically silent, reinforcing the need for routine endoscopic staging.
This review summarizes the evolving Japanese MCL treatment landscape, highlighting novel therapies like BTKi, BCL2i, and CAR-T to address resistance in high-risk subsets like TP53-mutated and blastoid.